Search Thermo Fisher Scientific
Advanced assay design to compensate for emerging SARS-CoV-2 mutations
In order to provide increased confidence in our COVID-19 test results as SARS-CoV-2 continues to mutate, our TaqPath COVID-19 2.0 tests employ an advanced assay design with increased target redundancy to compensate for both currently known and future SARS-CoV-2 mutations.
Assay design
Blog series: The Next Generation of COVID-19 Testing
This design is used across both of our TaqPath COVID-19 2.0 tests.
TaqPath COVID-19 2.0 assay details
CE-IVD Kit
Internal control
Sample type
Limit of detection
Turnaround time
(sample to result)
Approved sample
preparation
Approved system
and software
TaqPath COVID-19 Fast PCR Combo Kit 2.0
Download flyer ›
RNase P
Raw saliva
750–1,000 GCE/mL*
~2 hours
Lysis (Applied Biosystems
SalivaReady Solution–
Assay design, included in the combo kit)
- QuantStudio 5 Real-Time PCR System
(96-well, 0.2 mL) - QuantStudio 7 Flex Real-Time PCR System
(384-well) - Applied Biosystems Pathogen Interpretive Software
TaqPath COVID-19 RNase P Combo Kit 2.0
Download flyer ›
- Nasopharyngeal swab (NPS)
- Anterior nasal (nasal) swab
75 GCE/mL**
~3 hours
Thermo Scientific KingFisher
Flex Purification System with
Applied Biosystems MagMAX
Viral/Pathogen II Nucleic Acid Isolation Kit
- QuantStudio 5 Real-Time PCR System
(96-well, 0.2 mL) - QuantStudio 5 Dx Real-Time PCR System (96-well, 0.2 mL)
- QuantStudio 7 Flex Real-Time PCR System
(384-well) - Applied Biosystems Pathogen Interpretive Software
CE-IVD Kit | Internal control | Sample type | Limit of detection | Turnaround time | Approved sample | Approved system |
|---|---|---|---|---|---|---|
TaqPath COVID-19 Fast PCR Combo Kit 2.0Download flyer › | RNase P
| Raw saliva | 750–1,000 GCE/mL* | ~2 hours | Lysis (Applied Biosystems |
|
TaqPath COVID-19 RNase P Combo Kit 2.0Download flyer › |
| 75 GCE/mL**
| ~3 hours | Thermo Scientific KingFisher Applied Biosystems MagMAX |
|
*LOD of 750 GCE/mL using QuantStudio 7 Flex instrument (384-well); LOD of 1,000 GCE/mL using QuantStudio 5 instrument (96-well, 0.2 mL). LOD was determined using pooled, contrived raw saliva samples that were spiked with gamma-irradiated SARS-CoV-2, Isolate USA-WA1/2020 (BEI Resources, PN NR-52287, LN 70033322).
** A bridging study yielded 100% positivity (20/20) at 1x LoD for the QuantStudio 5 Instrument (96-well, 0.2 mL)
TaqPath COVID-19 2.0 test assays
Thermo Fisher Scientific continues to provide gold standard testing technology with our evolved PCR-based TaqPath COVID-19 2.0 tests, which were developed to help laboratories quickly diagnose COVID-19 caused by SARS-CoV-2 infection.
Features of the TaqPath COVID-19 2.0 test assays:
- Same accuracy and reliability you’ve grown to trust—An advanced assay design compensates for current and emerging mutations, helping provide continued confidence in results now and into the future
- Multiple workflow options—Choose from 2 tests options: one utilizing a standard workflow that includes RNA extraction, and the second utilizing a fast, direct-to-PCR workflow with no RNA extraction required
- Affordable and scalable—Add to your existing COVID-19 test menu using your current real-time PCR instrumentation
- Easier storage—Store your TaqPath COVID-19 2.0 combo kits at -20°C
Find your IFU
Find the approved Instructions for Use (IFU) for your country. (Note: Product availability varies by country.)
For In Vitro Diagnostic Use. Regulatory requirements vary by country. Product may not be available in your geographic region. © 2021 Thermo Fisher Scientific Inc.
All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.
Style Sheet for Global Design System
Style Sheet for Komodo Tabs